ProMetic Life Sciences Inc. (PLI) Director Sells C$131,523.20 in Stock
ProMetic Life Sciences Inc. (TSE:PLI) Director Louise Ménard sold 82,202 shares of the stock in a transaction on Monday, July 10th. The stock was sold at an average price of C$1.60, for a total value of C$131,523.20.
Shares of ProMetic Life Sciences Inc. (TSE PLI) traded down 4.32% during midday trading on Tuesday, reaching $1.55. The company had a trading volume of 1,010,790 shares. The company’s 50 day moving average price is $1.95 and its 200-day moving average price is $2.11. ProMetic Life Sciences Inc. has a 52 week low of $1.47 and a 52 week high of $3.24. The company’s market capitalization is $1.04 billion.
TRADEMARK VIOLATION WARNING: “ProMetic Life Sciences Inc. (PLI) Director Sells C$131,523.20 in Stock” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/07/11/prometic-life-sciences-inc-pli-director-sells-c131523-20-in-stock.html.
A number of equities research analysts recently weighed in on the company. Royal Bank Of Canada dropped their price objective on ProMetic Life Sciences from C$4.25 to C$4.00 and set an “outperform” rating on the stock in a research report on Monday, April 3rd. Scotiabank reaffirmed an “outperform” rating and set a C$4.75 price objective on shares of ProMetic Life Sciences in a research report on Wednesday, April 19th. TD Securities set a C$4.50 price objective on ProMetic Life Sciences and gave the company a “speculative buy” rating in a research report on Monday, April 3rd. Finally, Canaccord Genuity dropped their price objective on ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating on the stock in a research report on Monday, June 19th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. ProMetic Life Sciences has an average rating of “Buy” and an average price target of C$4.37.
About ProMetic Life Sciences
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.